Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 15/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4307025 | 0.82 | SLC6A4 (0.43) | SLC6A4SLC6A2SLC6A3CYP2D6MEN1 | |
| SCHEMBL1855360 | 0.80 | CHRM2 (0.46) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL4764069 | 0.76 | MEN1 (0.43) | SLC6A4SLC6A2SLC6A3CYP2D6MEN1 | |
| SCHEMBL3268419 | 0.76 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL7447748 | 0.74 | MEN1 (0.67) | SLC6A4SLC6A2CYP2D6CYP3A4MEN1 | |
| SCHEMBL2173663 | 0.73 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL3246700 | 0.71 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL9933670 | 0.70 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL3453995 | 0.70 | SLC6A2 (0.61) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL28854342 | 0.70 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346832-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | Glaxo Group Limited (GB) | 2011-07-27 | — | — | EP | claimed |
| WO-2010049366-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-05-06 | — | — | WO | claimed |
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| EP-2346832-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | Glaxo Group Limited (GB) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010049366-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GRM5, GRM1, GRM3 | SLC6A4 173/4885SLC6A2 474/4885SLC6A3 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.